ClinicalTrials.gg
RecruitingNCT06795152Updated Jan 7, 2026

Rare Glycogen Storage Diseases Natural History Study

An observational study in Glycogen Storage Disease, GSD Type 0A and GSD Type 0B, sponsored by Duke University. Recruiting at 1 site in United States. Open to participants aged 0 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-01-07.

Sponsored by Duke University · Observational

How we know

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
0 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 16 studies in Glycogen Storage Disease with a site in United States — 5 open to participants now, 6 under way, none of them phase 3. Glycogen Storage Disease · United States.

Started
2024
the only one that year
Observational
8 of 16
2 open now
Registered
13th of 16
by date
Lead sponsor
3 of 16
Duke University

Among the 16 studies in Glycogen Storage Disease with a site in United States, this one is the only one that started in 2024, is one of 8 observational ones, and was the 13th registered.

Glycogen Storage Disease

36 studies on the registry are indexed under Glycogen Storage Disease; 13 are open to participants now.

Browse Glycogen Storage Disease studies →

Open to participants now

5 of the 16 studies in Glycogen Storage Disease with a site in United States are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 9 Glycogen Storage Disease studies recruiting now, 4 set no upper age limit and 4 stop at 75 or younger; 6 take children under 18; 2 take healthy volunteers.

This study: 0 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Glycogen Storage Disease with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to collect and study key medical data about several ultra-rare GSDs (Glycogen Storage Diseases) including, but not limited to, GSD types 0a, 0b, VII, X, XII, XIII, XV, PRKAG2 syndrome and Danon disease.

Read the detailed description

The immediate goal of this research is to create a natural history database to collect information from individuals who have a rare GSD. A repository of clinical, laboratory, and biochemical information on individuals with a rare GSD will allow a more definitive description of the different subtypes to be developed, which will permit development of treatment strategies in the future.

Duke will be the only site where this study takes place. However, since these are rare disorders, participants who receive care at other institutions will be included. The investigators will collect retrospective data from patient charts on diagnosed individuals, as far back as necessary to capture the clinical course of their disorder. Prospective data collected from patient charts after enrollment will be captured as well. Participant's medical records will be continually reviewed for the duration of the study.

Data will be collected from medical records and will only pertain to clinically relevant information, including, but not limited to: demographic and diagnostic information, tissue biopsy results, medical and family history, review of systems, imaging studies, results of liver, muscle, and nerve function testing, and urine and blood laboratory results.

03

Conditions studied

  • Glycogen Storage Disease
  • GSD Type 0A
  • GSD Type 0B
  • GSD VII
  • Tarui Disease
  • GSD X
  • GSD XII
  • GSD XIII
  • GSD XV
  • PGBM2
  • PRKAG2
  • Danon Disease
  • Polyglucosan Body Myopathy Type 1
  • Polyglucosan Body Myopathy Type 2
  • RBCK1 Deficiency

Keywords

  • glycogen storage disease
  • GSD
  • Tarui disease
  • Polyglucosan Body Myopathy Type 2
  • PGBM2
  • PRKAG2
  • Danon disease
  • Polyglucosan Body Myopathy Type 1
  • RBCK1
04

Who can participate

Ages eligible
0 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All patients with rare GSD, including 0a, 0b, VII, X, XII, XIII, XV, PRKAG2 syndrome and Danon disease regardless of gender or ethnicity, are eligible for enrollment

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of a rare GSD, including 0a, 0b, VII, X, XII, XIII, XV, PRKAG2 syndrome or Danon disease

    • Two variants in the gene associated with the specific GSD type (for autosomal recessive diseases)
    • One variant in the gene associated with the specific GSD type (for autosomal dominant or X-linked diseases)
    • Deficient enzyme activity in liver, muscle, skin fibroblast or other tissue
    • One variant in causative gene with evidence of disease, per a clinician
    • Histology as confirmed by a clinician
  • Able to provide for self (adults) or affected individual (minor or adults with a legally authorized representative)
  • Able to provide consent for release of medical records
  • Pregnant women with a diagnosis of a rare GSD will be included

Exclusion criteria

Exclusion Criteria:

  • Unable to provide for participation for one's self or by legally authorized representative/legal guardian/parent
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Patient registry
No

Groups and cohorts

  • Rare GSD (Glycogen Storage Disease)

    individuals with confirmed diagnosis of rare glycogen storage disease including but not limited to, GSD types 0a, 0b, VII, X, XII, XIII, XV, PRKAG2 syndrome and Danon disease

    Other: No intervention

Interventions

  • OtherNo intervention

    Observational. Natural history study.

06

What researchers measure

Primary outcomes

  1. Progression of disease confirmed by medical record review

    Time frame: through study completion, an average of 10 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2024 (actual). Primary completion is estimated for Dec 2034, 120 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 22, 2025
First posted
Jan 27, 2025
StartActual
Dec 23, 2024
Primary completionEst.
Dec 2034
CompletionEst.
Dec 2034
Last update
Jan 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06795152
Lead sponsor
Duke University
Responsible party
Sponsor
First posted
Jan 27, 2025
Start date
Dec 23, 2024
Primary completion
Dec 2034 (estimated)
Completion
Dec 2034 (estimated)
Last update
Jan 7, 2026

Study contacts

Rebecca Koch, PhD, RDN
Contact
rebecca.koch@duke.edu
919-681-8823
Nisha Dalal, MS, CCC-SLP
Contact
nisha.dalal@duke.edu
919-668-3107
Priya Kishnani, M.D.
principal investigator · Duke

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion